Havas ECS

By Rob Dhoble, Managing Director at Havas ECS. What if physicians in all 50 states consistently understood the endocannabinoid system (ECS), and the extensive clinical data supporting use of medical cannabis, prescription cannabinoids, and hemp-derived non-prescription cannabinoids? Would each US...

On Saturday, former vice president and Democratic presidential candidate Joe Biden came out against federal legalization of cannabis. "The truth of the matter is, there's not nearly been enough evidence that has been acquired as to whether or not it is a gateway drug," said...

"Genetics" is a word that is often tossed around in the cannabis industry. Even before the boom in legal cannabis, plant enthusiasts knew the value that gene science could add to the recreational and medical experience. For the most part, efforts in genetic research surrounding...

Havas ECS, the endocannabinoid consultancy firm that’s a subsidiary of international advertising and public relations company Havas Group (owned by Vivendi SA (OTC: VIVEF)), last week announced the launch of a full spectrum education program for the medical and legal communities, aimed...

Earlier this month, the French multinational advertising and public relations giant Havas announced the release of its cannabis division: Havas ECS. The company, which is majority-owned by Vivendi SA (OTC: VIVEF) (OTC: VIVHY), announced it would open offices in New York and New Jersey...

The international advertising and public relations company Havas Group, which is majority-owned by Vivendi SA (OTC: VIVEF) (OTC: VIVHY), has launched a cannabis consultancy firm: Havas ECS. What Happened The multi-office venture aims to become a “specialized strategic communications...